A Randomized, Double-blind, 2-Way Crossover Bioequivalence and Adhesion Study of a Transdermal Contraceptive Patch Manufactured With Newly Sourced Adhesive Components and Currently Marketed EVRA in Healthy Adult Women
Phase of Trial: Phase IV
Latest Information Update: 26 Jun 2018
Price : $35 *
At a glance
- Drugs Norelgestromin (Primary) ; Ethinylestradiol/norelgestromin
- Indications Pregnancy
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Janssen Research & Development
- 15 Jun 2018 Status changed from recruiting to completed.
- 03 Oct 2017 Status changed from not yet recruiting to recruiting.
- 08 Sep 2017 New trial record